SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for ...

FDA granted Orphan Drug Designation to Sanofi’s SAR446523, a monoclonal antibody targeting GPRC5D, for relapsed/refractory ...

The FDA greenlit multiple new drugs this month and issued some notable label expansions, including for Eli Lilly’s Kisunla.

Sanofi’s Sarclisa (isatuximab) has been approved by the European Commission (EC) to treat newly diagnosed multiple myeloma ...

Sanofi's SAR446523 gains FDA orphan drug status, offering hope for relapsed multiple myeloma patients with its targeted ...

Sanofi (NASDAQ:SNY) ranks among the best medical stocks to buy according to analysts. On July 25, Sanofi (NASDAQ:SNY) ...

The first commercial for Johnson & Johnson and Legend Biotech’s Carvykti focuses on the numbers that make up a multiple ...

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

Medically reviewed by Archana Sharma, DO Diagnosing multiple myeloma, also referred to as myeloma, is often a complex process. While this rare blood cancer can cause many complications, it can't be ...

Curing multiple myeloma requires treatment until signs of the disease are undetectable. However, doing so requires consensus around an endpoint that provides meaningful insight into disease burden.

Multiple myeloma and myelofibrosis are both rare blood cancers. But they have distinct features that set them apart from one another. Though it’s unusual, you can develop these two cancers at ...

Multiple myeloma – a rare form of blood cancer – is usually found in people 65 and older. While it’s rare in young adults, a small percentage of people 19-40 also have the disease.